Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954547 | 1.00 | HDAC1 (0.72) | HDAC1SMN1; SMN2ALDH1A1KMT2AHDAC3 | |
| SCHEMBL1430230 | 0.86 | KMT2A (0.55) | HDAC1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL15549974 | 0.85 | HDAC1 (1.00) | HDAC1SMN1; SMN2ALDH1A1KMT2AHDAC3 | |
| SCHEMBL4726032 | 0.83 | HDAC1 (0.56) | HDAC1ALDH1A1KMT2AHDAC3HDAC2 | |
| SCHEMBL11022909 | 0.79 | HDAC1 (0.49) | HDAC1ALDH1A1KMT2AHDAC3HDAC2 | |
| SCHEMBL12247210 | 0.79 | ALDH1A1 (0.50) | HDAC1SMN1; SMN2ALDH1A1KMT2AHDAC3 | |
| SCHEMBL2792321 | 0.79 | HDAC1 (0.49) | HDAC1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL27562738 | 0.79 | HDAC1 (0.49) | HDAC1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL3598057 | 0.79 | ALDH1A1 (0.50) | HDAC1SMN1; SMN2ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL20050944 | 0.79 | HDAC1 (0.52) | HDAC1ALDH1A1KMT2AHDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084678-A | Preparation method of 2-bromo-6-fluoroaniline | 长沙唯楚医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118084678-A | Preparation method of 2-bromo-6-fluoroaniline | 长沙唯楚医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084678-A | Preparation method of 2-bromo-6-fluoroaniline | 长沙唯楚医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2419423-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | Cellzome Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | HDAC1 2889/4885SMN1; SMN2 4457/4885ALDH1A1 2492/4885 |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | HDAC1 2765/4885SMN1; SMN2 4196/4885ALDH1A1 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.